Enovis Announces Second Quarter 2023 Results and Raises Full-Year Outlook
- Enovis reported strong sales growth of 8% in Q2 2023, with 17% organic growth in the Reconstructive segment and 4% in the Prevention and Recovery segment.
- The company's adjusted EBITDA margin improved by 110 basis points versus the prior year quarter.
- Enovis updated its 2023 revenue growth expectation to 7-7.5% and adjusted EBITDA forecast to $262-$270 million.
- None.
- Continued strong momentum with second quarter sales growth of
8% and strong EBITDA margin expansion - Organic growth of 17% in Recon and
4% in P&R - Reported a second quarter net loss from continuing operations of
$0. 27 per share with adjusted earnings per diluted share of$0. 61
Wilmington, DE, Aug. 03, 2023 (GLOBE NEWSWIRE) -- —Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended June 30, 2023. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.
Second Quarter 2023 Financial Results
Enovis’ second quarter net sales of
Enovis also reported a second quarter net loss from continuing operations of
The Company reported a second quarter 2023 net loss from continuing operations of
“We are very pleased with our first half 2023 results of high-single digit growth and strong margin expansion,” said Matt Trerotola, Chief Executive Officer of Enovis. “We continue to make progress on our strategic goals and have robust operating momentum in both of our business segments. As we look to the balance of the year, we will maintain our focus on innovation-driven share gain, operational improvement with EGX, and compounding impact from M&A.”
Second Quarter 2023 Business Highlights
- Strong double-digit Reconstructive growth across anatomies
- Gross margin improved yr/yr for the fourth quarter in a row
- Recognized as One of America’s Greatest Workplaces by Newsweek
2023 Financial Outlook
Enovis updated its financial expectations for 2023. Revenue is expected to organically grow 7
Conference call and Webcast
Investors can access the webcast via a link on the Enovis website, www.enovis.com. For those planning to participate on the call, please dial (833) 630-1956 (U.S. callers) or +1 (412) 317-1873 (International callers) and ask to join the Enovis call. A link to a replay of the call will also be available on the Enovis website later in the day.
ABOUT ENOVIS
Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company’s shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit www.enovis.com.
Forward-Looking Statements
This press release includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis’ plans, goals, objectives, outlook, expectations and intentions, and other statements that are not historical or current fact. Forward-looking statements are based on Enovis’ current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Enovis’ results to differ materially from current expectations include, but are not limited to, risks related to the impact of the COVID-19 global pandemic; the war in Ukraine and escalating geopolitical tensions as a result of Russia’s invasion of Ukraine; macroeconomic conditions, including the impact of increasing inflationary pressures; supply chain disruptions; increasing energy costs and availability concerns, particularly in the European market; the impacts of the completed spin-off of ESAB Corporation into an independent publicly traded company (the “Separation”); the potential to incur significant liability if the Separation is determined to be a taxable transaction; the ability to realize the anticipated benefits of the Separation; the financial and operating performance of the Company following the Separation; other impacts on Enovis’ business and ability to execute business continuity plans; and the other factors detailed in Enovis’ reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors,” as well as the other risks discussed in Enovis’ filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This press release speaks only as of the date hereof. Enovis disclaims any duty to update the information herein.
Non-GAAP Financial Measures
Enovis has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America (“non-GAAP”). These non-GAAP financial measures may include one or more of the following: adjusted net income from continuing operations, adjusted net income per diluted share from continuing operations, adjusted EBITDA (earnings before interest, taxes, depreciation and amortization), adjusted EBITDA margin and organic sales growth.
Adjusted net income from continuing operations and Adjusted net income per diluted share from continuing operations excludes restructuring and other charges, European Union Medical Device Regulation (“MDR”) and other costs, amortization of acquired intangibles, inventory step up costs, strategic transaction costs, debt extinguishment costs, insurance settlement gain, gains and losses on the Company’s investments, stock compensation costs, and other income/expense. Adjusted net income adjusts interest expense for periods prior to 2023 to reflect pro forma interest from the Company’s term loan facility under the Company’s current capital structure after giving effect to the completing of the refinancing transactions in connection with the Separation, and it includes the tax effect of adjusted pre-tax income at applicable tax rates and other tax adjustments. Enovis also presents adjusted net income margin from continuing operations, which is subject to the same adjustments as adjusted net income from continuing operations.
Adjusted EBITDA represents net income or loss from continuing operations excluding taxes, depreciation and amortization, stock-based compensation costs and restructuring and other charges, MDR and other costs, strategic transaction costs, insurance settlement (gain) loss, and inventory step up costs. Enovis presents adjusted EBITDA margin, which is subject to the same adjustments as adjusted EBITDA.
Organic sales growth excludes the impact of acquisitions and foreign exchange rate fluctuations.
These non-GAAP financial measures assist Enovis management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans that are fundamentally different from the ongoing productivity improvements of the Company. Enovis management also believes that presenting these measures allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of non-GAAP financial measures presented above to GAAP results has been provided in the financial tables included in this press release. Enovis does not provide reconciliations of adjusted EBITDA or adjusted earnings per share on a forward-looking basis to the closest GAAP financial measures, as such information is not available without unreasonable efforts on a forward-looking basis due to uncertainties regarding, and the potential variability of, reconciling items excluded from these measures. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period.
Derek Leckow
Vice President, Investor Relations
Enovis Corporation
+1-302-421-1971
investorrelations@enovis.com
Enovis Corporation
Condensed Consolidated Statements of Operations
Dollars in thousands, except per share data
(Unaudited)
| Three Months Ended | Six Months Ended | ||||||||||||||
| June 30, 2023 | July 1, 2022 | June 30, 2023 | July 1, 2022 | ||||||||||||
| Net sales | $ | 428,502 | $ | 395,117 | $ | 834,653 | $ | 770,574 | |||||||
| Cost of sales | 180,143 | 179,211 | 351,229 | 348,768 | |||||||||||
| Gross profit | 248,359 | 215,906 | 483,424 | 421,806 | |||||||||||
| Gross profit margin | 58.0 | % | 54.6 | % | 57.9 | % | 54.7 | % | |||||||
| Selling, general and administrative expense | 207,881 | 193,657 | 415,046 | 382,137 | |||||||||||
| Research and development expense | 18,918 | 15,661 | 37,111 | 30,503 | |||||||||||
| Amortization of acquired intangibles | 32,249 | 31,824 | 64,289 | 62,610 | |||||||||||
| Insurance settlement gain | — | (33,034) | — | (33,034) | |||||||||||
| Restructuring and other charges | 3,805 | 2,245 | 6,440 | 4,664 | |||||||||||
| Operating income (loss) | (14,494) | 5,553 | (39,462) | (25,074) | |||||||||||
| Operating income (loss) margin | (3.4) % | 1.4 | % | (4.7) % | (3.3) % | ||||||||||
| Interest expense, net | 4,076 | 4,546 | 9,728 | 11,610 | |||||||||||
| Debt extinguishment charges | — | 20,104 | — | 20,104 | |||||||||||
| Unrealized gain on investment in ESAB Corporation | — | (135,537) | — | (135,537) | |||||||||||
| Other expense, net | 753 | — | 92 | — | |||||||||||
| Income (loss) from continuing operations before income taxes | (19,323) | 116,440 | (49,282) | 78,749 | |||||||||||
| Income tax benefit | (4,713) | (4,211) | (11,826) | (3,847 ) | |||||||||||
| Net income (loss) from continuing operations | (14,610) | 120,651 | (37,456) | 82,596 | |||||||||||
| Income (loss) from discontinued operations, net of taxes | 4,797 | (43,666) | 4,485 | 10,690 | |||||||||||
| Net income (loss) | (9,813) | 76,985 | (32,971) | 93,286 | |||||||||||
| Less: net income attributable to noncontrolling interest from continuing operations - net of taxes | 182 | 130 | 374 | 397 | |||||||||||
| Less: net income attributable to noncontrolling interest from discontinued operations - net of taxes | — | — | — | 966 | |||||||||||
| Net income (loss) attributable to Enovis Corporation | $ | (9,995) | $ | 76,855 | $ | (33,345) | $ | 91,923 | |||||||
| Net income (loss) per share - basic | |||||||||||||||
| Continuing operations | $ | (0.27) | $ | 2.23 | $ | (0.70) | $ | 1.52 | |||||||
| Discontinued operations | $ | 0.09 | $ | (0.81) | $ | 0.08 | $ | 0.18 | |||||||
| Consolidated operations | $ | (0.18) | $ | 1.42 | $ | (0.61) | $ | 1.70 | |||||||
| Net income (loss) per share - diluted | |||||||||||||||
| Continuing operations | $ | (0.27 | ) | $ | 2.21 | $ | (0.70 | ) | $ | 1.51 | |||||
| Discontinued operations | $ | 0.09 | $ | (0.80 | ) | $ | 0.08 | $ | 0.18 | ||||||
| Consolidated operations | $ | (0.18 | ) | $ | 1.41 | $ | (0.61 | ) | $ | 1.69 | |||||
Enovis Corporation
Reconciliation of GAAP to non-GAAP Financial Measures
Change in Sales
Dollars in millions
(Unaudited)
| Net Sales | |||||||||||||||||
| Prevention and Recovery | Reconstructive | Total Enovis | |||||||||||||||
| $ | Change % | $ | Change % | $ | Change % | ||||||||||||
| For the three months ended July 1, 2022 | $ | 263.8 | $ | 131.3 | $ | 395.1 | |||||||||||
| Components of Change: | |||||||||||||||||
| Existing businesses(1) | 9.6 | 3.6 | % | 21.8 | 16.6 | % | 31.4 | 7.9 | % | ||||||||
| Acquisitions(2) | — | — | % | 0.9 | 0.7 | % | 0.9 | 0.2 | % | ||||||||
| Foreign currency translation(3) | 0.1 | — | % | 1.0 | 0.8 | % | 1.1 | 0.3 | % | ||||||||
| 9.7 | 3.7 | % | 23.7 | 18.1 | % | 33.4 | 8.4 | % | |||||||||
| For the three months ended June 30, 2023 | $ | 273.5 | $ | 155.0 | $ | 428.5 | |||||||||||
| Net Sales | ||||||||||||||||||||
| Prevention and Recovery | Reconstructive | Total Enovis | ||||||||||||||||||
| $ | Change % | $ | Change % | $ | Change % | |||||||||||||||
| For the six months ended July 1, 2022 | $ | 508.6 | $ | 262.0 | $ | 770.6 | ||||||||||||||
| Components of Change: | ||||||||||||||||||||
| Existing businesses(1) | 19.7 | 3.9 | % | 46.9 | 17.9 | % | 66.6 | 8.6 | % | |||||||||||
| Acquisitions(2) | — | — | % | 2.1 | 0.8 | % | 2.1 | 0.3 | % | |||||||||||
| Foreign currency translation(3) | (4.1 | ) | (0.8) % | (0.4 | ) | (0.2) % | (4.5 | ) | (0.6) % | |||||||||||
| 15.6 | 3.1 | % | 48.4 | 18.5 | % | 64.1 | 8.3 | % | ||||||||||||
| For the six months ended June 30, 2023 | $ | 524.2 | $ | 310.4 | $ | 834.7 | ||||||||||||||
(1) Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of growth due to factors such as price, product mix and volume.
(2) Represents the incremental sales as a result of acquisitions closed subsequent to the beginning of the prior year period.
(3) Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.
Enovis Corporation
Reconciliation of GAAP to Non-GAAP Financial Measures
Dollars in millions, except per share data
(Unaudited)
| Three Months Ended | Six Months Ended | ||||||||||||||
| June 30, 2023 | July 1, 2022 | June 30, 2023 | July 1, 2022 | ||||||||||||
| Adjusted Net Income and Adjusted Net Income Per Share | |||||||||||||||
| Net income (loss) from continuing operations attributable to Enovis Corporation(1) (GAAP) | $ | (14.8 | ) | $ | 120.5 | $ | (37.8 | ) | $ | 82.2 | |||||
| Restructuring and other charges - pretax(2) | 3.8 | 2.6 | 6.7 | 5.5 | |||||||||||
| MDR and other costs - pretax(3) | 9.0 | 4.4 | 16.8 | 7.0 | |||||||||||
| Amortization of acquired intangibles - pretax | 32.2 | 31.8 | 64.3 | 62.6 | |||||||||||
| Inventory step-up - pretax | — | 4.9 | 0.1 | 10.0 | |||||||||||
| Strategic transaction costs - pretax(4) | 5.4 | 12.7 | 17.1 | 24.4 | |||||||||||
| Debt extinguishment charges - pretax | — | 20.1 | — | 20.1 | |||||||||||
| Pro forma interest expense adjustment(5) | — | 3.3 | — | 9.5 | |||||||||||
| Insurance settlement gain(6) | — | (33.0 | ) | — | (33.0 | ) | |||||||||
| Unrealized gain on investment in ESAB Corporation | — | (135.5 | ) | — | (135.5 | ) | |||||||||
| Stock-based compensation | 8.9 | 7.8 | 15.8 | 14.5 | |||||||||||
| Other expense, net | 0.8 | — | 0.1 | — | |||||||||||
| Tax adjustment(6) | (12.0 | ) | (7.4 | ) | (25.5 | ) | (14.9 | ) | |||||||
| Adjusted net income from continuing operations (non-GAAP) | $ | 33.4 | $ | 32.2 | $ | 57.5 | $ | 52.5 | |||||||
| Adjusted net income margin from continuing operations | 7.8 | % | 8.2 | % | 6.9 | % | 6.8 | % | |||||||
| Weighted-average shares outstanding - diluted (in thousands) | 54,934 | 54,522 | 54,885 | 54,459 | |||||||||||
| Adjusted net income per share - diluted from continuing operations (non-GAAP) | $ | 0.61 | $ | 0.59 | $ | 1.05 | $ | 0.96 | |||||||
| Net loss per share - diluted from continuing operations (GAAP) | $ | (0.27 | ) | $ | 2.21 | $ | (0.70 | ) | $ | 1.51 | |||||
__________
(1) Net loss from continuing operations attributable to Enovis Corporation for the respective periods is calculated using Net loss from continuing operations less the continuing operations component of the income attributable to noncontrolling interest, net of taxes, of
(2) Restructuring and other charges includes $— million and
(3) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union MDR. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.
(4) Strategic transaction costs includes costs related to the Separation and certain transaction and integration costs related to recent acquisitions.
(5) Adjusts interest expense in 2022 to reflect pro forma interest from the Company’s term loan facility after giving effect to the completion of the refinancing transactions in connection with the Separation.
(6) The effective tax rates used to calculate adjusted net income and adjusted net income per share were
Enovis Corporation
Reconciliation of GAAP to Non-GAAP Financial Measures
Dollars in millions
(Unaudited)
| Three Months Ended | Six Months Ended | ||||||||||||||
| June 30, 2023 | July 1, 2022 | June 30, 2023 | July 1, 2022 | ||||||||||||
| (Dollars in millions) | |||||||||||||||
| Net income (loss) from continuing operations (GAAP) | $ | (14.6 | ) | $ | 120.7 | $ | (37.5 | ) | $ | 82.6 | |||||
| Income tax benefit | (4.7 | ) | (4.2 | ) | (11.8 | ) | (3.8 | ) | |||||||
| Other expense, net | 0.8 | — | 0.1 | — | |||||||||||
| Gain on investment in ESAB Corporation | — | (135.5 | ) | — | (135.5 | ) | |||||||||
| Debt extinguishment charges | — | 20.1 | — | 20.1 | |||||||||||
| Interest expense, net | 4.1 | 4.5 | 9.7 | 11.6 | |||||||||||
| Operating income (loss) (GAAP) | (14.5 | ) | 5.6 | (39.5 | ) | (25.1 | ) | ||||||||
| Adjusted to add: | |||||||||||||||
| Restructuring and other charges(1) | 3.8 | 2.6 | 6.7 | 5.5 | |||||||||||
| MDR and other costs(2) | 9.0 | 4.4 | 16.8 | 7.0 | |||||||||||
| Strategic transaction costs(3) | 5.4 | 12.7 | 17.1 | 24.4 | |||||||||||
| Stock-based compensation | 8.9 | 7.8 | 15.8 | 14.5 | |||||||||||
| Depreciation and other amortization | 20.8 | 19.5 | 40.7 | 38.0 | |||||||||||
| Amortization of acquired intangibles | 32.2 | 31.8 | 64.3 | 62.6 | |||||||||||
| Insurance settlement gain | — | (33.0 | ) | — | (33.0 | ) | |||||||||
| Inventory step-up | — | 4.9 | 0.1 | 10.0 | |||||||||||
| Adjusted EBITDA (non-GAAP) | $ | 65.7 | $ | 56.2 | $ | 122.1 | $ | 103.9 | |||||||
| Adjusted EBITDA margin (non-GAAP) | 15.3 | % | 14.2 | % | 14.6 | % | 13.5 | % | |||||||
__________
(1) Restructuring and other charges includes $— million and
(2) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union MDR. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.
(3) Strategic transaction costs includes costs related to the Separation and certain transaction and integration costs related to recent acquisitions.
Enovis Corporation
Condensed Consolidated Balance Sheets
Dollars in thousands, except share amounts
(Unaudited)
| June 30, 2023 | December 31, 2022 | ||||||
| ASSETS | |||||||
| CURRENT ASSETS: | |||||||
| Cash and cash equivalents | $ | 32,491 | $ | 24,295 | |||
| Trade receivables, less allowance for credit losses of | 298,976 | 267,380 | |||||
| Inventories, net | 453,897 | 426,643 | |||||
| Prepaid expenses | 26,758 | 28,550 | |||||
| Other current assets | 75,117 | 48,155 | |||||
| Total current assets | 887,239 | 795,023 | |||||
| Property, plant and equipment, net | 260,754 | 236,741 | |||||
| Goodwill | 2,034,087 | 1,983,588 | |||||
| Intangible assets, net | 1,110,950 | 1,110,727 | |||||
| Lease asset - right of use | 61,739 | 66,881 | |||||
| Other assets | 88,784 | 80,288 | |||||
| Total assets | $ | 4,443,553 | $ | 4,273,248 | |||
| LIABILITIES AND EQUITY | |||||||
| CURRENT LIABILITIES: | |||||||
| Current portion of long-term debt | $ | — | $ | 219,279 | |||
| Accounts payable | 147,180 | 135,628 | |||||
| Accrued liabilities | 206,493 | 210,292 | |||||
| Total current liabilities | 353,673 | 565,199 | |||||
| Long-term debt, less current portion | 400,000 | 40,000 | |||||
| Non-current lease liability | 47,567 | 51,259 | |||||
| Other liabilities | 191,553 | 166,989 | |||||
| Total liabilities | 992,793 | 823,447 | |||||
| Equity: | |||||||
| Common stock, | 55 | 54 | |||||
| Additional paid-in capital | 2,944,094 | 2,925,729 | |||||
| Retained earnings | 542,387 | 575,732 | |||||
| Accumulated other comprehensive loss | (37,898 | ) | (53,430 | ) | |||
| Total Enovis Corporation equity | 3,448,638 | 3,448,085 | |||||
| Noncontrolling interest | 2,122 | 1,716 | |||||
| Total equity | 3,450,760 | 3,449,801 | |||||
| Total liabilities and equity | $ | 4,443,553 | $ | 4,273,248 | |||
Enovis Corporation
Condensed Consolidated Statements of Cash Flows
Dollars in thousands
(Unaudited)
| Six Months Ended | |||||||
| June 30, 2023 | July 1, 2022 | ||||||
| Cash flows from operating activities: | |||||||
| Net income (loss) | $ | (32,971 | ) | $ | 93,286 | ||
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | |||||||
| Depreciation, amortization and other impairment charges | 105,033 | 117,300 | |||||
| Stock-based compensation expense | 16,981 | 19,793 | |||||
| Non-cash interest expense | 1,481 | 1,658 | |||||
| Unrealized gain on investment in ESAB Corporation | — | (135,537 | ) | ||||
| Debt extinguishment charges | — | 20,104 | |||||
| Deferred income tax expense (benefit) | (107 | ) | 2,174 | ||||
| Loss on sale of property, plant and equipment | 533 | 352 | |||||
| Changes in operating assets and liabilities: | |||||||
| Trade receivables, net | (25,912 | ) | (33,123 | ) | |||
| Inventories, net | (10,476 | ) | (92,910 | ) | |||
| Accounts payable | 8,324 | 15,919 | |||||
| Other operating assets and liabilities | (27,326 | ) | (48,329 | ) | |||
| Net cash provided by (used in) operating activities | 35,560 | (39,313 | ) | ||||
| Cash flows from investing activities: | |||||||
| Purchases of property, plant and equipment and intangibles | (67,248 | ) | (47,796 | ) | |||
| Proceeds from sale of property, plant and equipment | — | 2,746 | |||||
| Acquisitions, net of cash received, and investments | (98,740 | ) | (35,123 | ) | |||
| Net cash used in investing activities | (165,988 | ) | (80,173 | ) | |||
| Cash flows from financing activities: | |||||||
| Payments under term credit facility | (219,468 | ) | (785,000 | ) | |||
| Proceeds from borrowings on revolving credit facilities and other | 370,000 | 450,000 | |||||
| Repayments of borrowings on revolving credit facilities and other | (11,538 | ) | (607,618 | ) | |||
| Repayments of borrowings on Euro senior notes | — | (386,278 | ) | ||||
| Repayments of borrowings on Senior notes | — | (300,000 | ) | ||||
| Distribution from ESAB Corporation, net | — | 1,143,369 | |||||
| Proceeds from issuance of common stock, net | 1,385 | 1,727 | |||||
| Payment of debt extinguishment costs | — | (12,704 | ) | ||||
| Deferred consideration payments and other | (1,668 | ) | (9,795 | ) | |||
| Net cash provided by (used in) financing activities | 138,711 | (506,299 | ) | ||||
| Effect of foreign exchange rates on Cash and cash equivalents | (87 | ) | 2,020 | ||||
| Increase (decrease) in Cash and cash equivalents | 8,196 | (623,765 | ) | ||||
| Cash and cash equivalents, beginning of period | 24,295 | 719,370 | |||||
| Cash and cash equivalents, end of period | $ | 32,491 | $ | 95,605 | |||
FAQ
What were Enovis Corporation's Q2 2023 sales growth figures?
What was the company's net loss from continuing operations in Q2 2023?
What are Enovis Corporation's updated financial expectations for 2023?
